Evidence map›Paper›PMID 40468683›Full record

ArticleFuture oncology (London, England)2025

Real-world survival outcomes and MDM2 prevalence in US patients with metastatic dedifferentiated liposarcoma.

Steven Robinson, Alyssa B Klein, Stephen A Stanhope, Kathryn Evans, Mark Agulnik

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Future oncology (London, England), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Review
  2. Observational
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Steven RobinsonDivision of Medical Oncology, Mayo Clinic, Rochester, MN, USA.ORCID 0000-0002-1648-1908
Alyssa B KleinGlobal Integrated Evidence, Boehringer Ingelheim Pharmaceuticals Inc, Ridgefield, CT, USA.
Stephen A StanhopeGlobal Integrated Evidence, Boehringer Ingelheim Pharmaceuticals Inc, Ridgefield, CT, USA.
Kathryn EvansReal-world Evidence, Evidera, Bethesda, MD, USA.
Mark AgulnikDepartment of Medicine, Division of Oncology, Keck Medicine of USC, Los Angeles, CA, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundLimited data exist regarding dedifferentiated liposarcoma (DDLPS) treatment, biomarker frequency, and clinical outcomes. Additional epidemiological data are needed to inform clinical trial design for testing novel therapeutics. MATERIALS AND

methodsRetrospective data from a US-based deidentified clinico-genomic database were analyzed for patients treated for metastatic DDLPS between 2011 and 2021.

resultsOverall survival (OS), real-world progression-free survival (rwPFS), and time to next treatment (TTNT) were described in the overall cohort (

conclusionsThe descriptive analysis here contributes real-world data describing treatment patterns, biomarker status, and clinical outcomes for patients with DDLPS, an aggressive and poorly characterized form of LPS with limited treatment options.

Indexed as

LiposarcomaProto-Oncogene Proteins c-mdm2AdultAgedAged, 80 and overAntineoplastic Combined Chemotherapy ProtocolsBiomarkers, TumorFemaleHumansMaleMiddle AgedPrevalencePrognosisProgression-Free SurvivalRetrospective StudiesTumor Suppressor Protein p53Biomarkers, TumorMDM2 protein, humanProto-Oncogene Proteins c-mdm2TP53 protein, humanTumor Suppressor Protein p53MDM2Metastatic dedifferentiated liposarcomareal-worldsurvivalTP53treatment patterns

Identifiers

PMID40468683
PMCPMC12150605

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.